Telcon RF Pharmaceutical Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
132
- Stock Symbol
-
200230
- Investments
-
9
- Share Price
-
$1.40
- (As of Thursday Closing)
Telcon RF Pharmaceutical General Information
Description
Telcon RF Pharmaceutical Inc manufactures wireless communication equipment. It develops connectors for input and output ports, board-to-board, cable assembly, and board-to-mount used in wireless communication equipment. The company also supplies RF coaxial connectors. The company operates in the RF Division and Pharmaceuticals & Biotechnology segments. The majority of its revenue is generated from Pharmaceuticals & Biotechnology, which produces and sells liquids, tablets, pills, capsules, etc.
Contact Information
Website
www.telcon.co.krCorporate Office
- 54, Gongse-ro
- Giheung-gu
- Yongin, Gyeonggi 17086
- South Korea
Corporate Office
- 54, Gongse-ro
- Giheung-gu
- Yongin, Gyeonggi 17086
- South Korea
Telcon RF Pharmaceutical Stock Performance
As of 12-Nov-2026, Telcon RF Pharmaceutical’s stock price is $1.40. Its current market cap is $10M with 7.14M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.40 | $1.41 | $1.18 - $8.13 | $10M | 7.14M | 26.6K | $4.34 |
Telcon RF Pharmaceutical Financials Summary
As of 30-Jun-2026, Telcon RF Pharmaceutical has a trailing 12-month revenue of $42.6M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,245 | 39,507 | 72,791 | 83,247 |
| Revenue | 42,573 | 30,329 | 27,752 | 27,769 |
| EBITDA | (12,536) | (1,740) | (13,601) | 14,232 |
| Net Income | (12,046) | (8,050) | (19,290) | 10,636 |
| Total Assets | 121,333 | 108,797 | 104,271 | 108,960 |
| Total Debt | 40,925 | 23,797 | 37,808 | 21,280 |
Telcon RF Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Telcon RF Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Telcon RF Pharmaceutical Patents
Telcon RF Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4145639-A1 | Connecting apparatus | Pending | 29-Apr-2020 | ||
| EP-4145639-A4 | Connecting apparatus | Pending | 29-Apr-2020 | ||
| WO-2021221473-A1 | Connecting apparatus | Inactive | 29-Apr-2020 | ||
| AU-2018101542-A4 | Hybrid connector | Inactive | 16-Oct-2018 | ||
| AU-2018101542-A6 | Hybrid connector | Inactive | 16-Oct-2018 | G02B6/3817 |
Telcon RF Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Telcon RF Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Telcon RF Pharmaceutical Investments & Acquisitions (9)
Telcon RF Pharmaceutical’s most recent deal was a PIPE with Abion (Drug Discovery) for . The deal was made on 23-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Abion (Drug Discovery) | 23-Dec-2024 | PIPE | Drug Discovery | ||
| Abion (Drug Discovery) | 19-Apr-2024 | Secondary Transaction - Open Market | Drug Discovery | ||
| Abion (Drug Discovery) | 20-Dec-2023 | PIPE | Drug Discovery | ||
| Kpm Tech | 31-Mar-2022 | PIPE | Industrial Chemicals | ||
| Abion (Drug Discovery) | 01-Jul-2020 | Secondary Transaction - Private | Drug Discovery |
Telcon RF Pharmaceutical ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
38.93 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,216
Rank
Percentile
Electrical Equipment
Industry
of 315
Rank
Percentile
Electrical Equipment
Subindustry
of 315
Rank
Percentile
Telcon RF Pharmaceutical FAQs
-
When was Telcon RF Pharmaceutical founded?
Telcon RF Pharmaceutical was founded in 1999.
-
Where is Telcon RF Pharmaceutical headquartered?
Telcon RF Pharmaceutical is headquartered in Yongin, South Korea.
-
What is the size of Telcon RF Pharmaceutical?
Telcon RF Pharmaceutical has 132 total employees.
-
What industry is Telcon RF Pharmaceutical in?
Telcon RF Pharmaceutical’s primary industry is Electrical Equipment.
-
Is Telcon RF Pharmaceutical a private or public company?
Telcon RF Pharmaceutical is a Public company.
-
What is Telcon RF Pharmaceutical’s stock symbol?
The ticker symbol for Telcon RF Pharmaceutical is 200230.
-
What is the current stock price of Telcon RF Pharmaceutical?
As of 12-Nov-2026 the stock price of Telcon RF Pharmaceutical is $1.40.
-
What is the current market cap of Telcon RF Pharmaceutical?
The current market capitalization of Telcon RF Pharmaceutical is $10M.
-
What is Telcon RF Pharmaceutical’s current revenue?
The trailing twelve month revenue for Telcon RF Pharmaceutical is $42.6M.
-
What is Telcon RF Pharmaceutical’s annual earnings per share (EPS)?
Telcon RF Pharmaceutical’s EPS for 12 months was $4.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
